Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1993 1
1994 1
1995 3
1996 11
1997 10
1998 11
1999 7
2000 11
2001 6
2002 5
2003 7
2004 5
2005 3
2006 2
2007 1
2008 7
2009 4
2010 3
2011 3
2012 2
2013 2
2014 2
2015 1
2016 2
2017 3
2018 1
2019 2
2020 6
2021 5
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Benchmarks for Academic Oncology Faculty.
Anthony L, Atweh G, Bhatia R, Carey LA, Chang JC, Edelman MJ, Kantoff PW, Markham MJ, Messersmith W, Nelson EL, Oettel K, O'Regan R, Verschraegen CF, Vose JM. Anthony L, et al. Among authors: verschraegen cf. JCO Oncol Pract. 2021 Mar;17(3):e440-e444. doi: 10.1200/OP.20.00020. Epub 2020 Sep 30. JCO Oncol Pract. 2021. PMID: 32997608 Free PMC article. Review.
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Owen DH, Benner B, Wei L, Sukrithan V, Goyal A, Zhou Y, Pilcher C, Suffren SA, Christenson G, Curtis N, Jukich M, Schwarz E, Savardekar H, Norman R, Ferguson S, Kleiber B, Wesolowski R, Carson WE, Otterson GA, Verschraegen CF, Shah MH, Konda B. Owen DH, et al. Among authors: verschraegen cf. Clin Cancer Res. 2023 Feb 16;29(4):731-741. doi: 10.1158/1078-0432.CCR-22-1552. Clin Cancer Res. 2023. PMID: 36255391 Free PMC article.
Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition.
Wargo JJ, Carr DR, Plaza JA, Verschraegen CF. Wargo JJ, et al. Among authors: verschraegen cf. J Natl Compr Canc Netw. 2022 Feb 23:1-3. doi: 10.6004/jnccn.2021.7119. Online ahead of print. J Natl Compr Canc Netw. 2022. PMID: 35196645
TLK-286.
Verschraegen CF, Smith HO, Lee FC, Cathcart C, Norenberg JP. Verschraegen CF, et al. IDrugs. 2004 Aug;7(8):771-81. IDrugs. 2004. PMID: 15334311 Review.
Malignant adnexal masses in pregnancy.
Sayar H, Lhomme C, Verschraegen CF. Sayar H, et al. Among authors: verschraegen cf. Obstet Gynecol Clin North Am. 2005 Dec;32(4):569-93. doi: 10.1016/j.ogc.2005.08.003. Obstet Gynecol Clin North Am. 2005. PMID: 16310673 Review.
Alternative administration of camptothecin analogues.
Glaberman U, Rabinowitz I, Verschraegen CF. Glaberman U, et al. Among authors: verschraegen cf. Expert Opin Drug Deliv. 2005 Mar;2(2):323-33. doi: 10.1517/17425247.2.2.323. Expert Opin Drug Deliv. 2005. PMID: 16296757 Review.
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Luke JJ, et al. Among authors: verschraegen cf. Clin Cancer Res. 2023 Jul 5;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. Clin Cancer Res. 2023. PMID: 37227176 Clinical Trial.
ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF, Glover K. Verschraegen CF, et al. Curr Opin Investig Drugs. 2001 Nov;2(11):1631-8. Curr Opin Investig Drugs. 2001. PMID: 11763168 Review.
Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?
Rittiluechai K, Wilcox R, Lisle J, Everett E, Wallace HJ 3rd, Verschraegen CF. Rittiluechai K, et al. Among authors: verschraegen cf. Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:25-9. doi: 10.1016/j.ejogrb.2013.12.029. Epub 2014 Jan 3. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24462393 Review.
125 results